• Zymeworks partnered with Gandeeva Therapeutics to generate cryo-EM structural data to support antibody drug discovery.
• Collaboration targets high-resolution mapping of antibody-antigen interfaces, including small, flexible antigens that are difficult to resolve.
• Teams produced a 2.6 Å cryo-EM structure of a Zymeworks antibody Fab bound to a <20 kDa flexible antigen.
• Work identified a nine–amino acid binding epitope, supporting lead selection and biologics optimization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606180800PR_NEWS_USPR_____VA85156) on June 18, 2026, and is solely responsible for the information contained therein.